Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Theriva Biologics Q3 2026 Results: Net Loss of $1.47M, Loss Narrows

Theriva Biologics reported a net loss of $6.7 million for the nine months ended September 30, 2026, a significant improvement from the $21.7 million loss in the prior year period. The company generated $0.3 million in license revenue and substantially reduced operating expenses, while maintaining a cash balance of $8.5 million as of the end of the quarter.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-1.5-4.4
Net income-1.5-4.4
EPS (diluted, $ a share)$-0.03$-0.45

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NYSE: TOVX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Theriva Biologics, Inc.: key numbers

Share price
$0.1400Close, Nov 17
Market cap
$6.42M
Shares outstanding
45.89MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Theriva Biologics, Inc.

All →
8:11 AM ET 8-K
Financial Results

Theriva Biologics Financial Results

Theriva Biologics reported third quarter 2026 financial results, highlighting a cash position of $8.5 million and a runway into Q1 2027. The company also noted the completion of the sale of its SYN-004 portfolio to Biossil Labs for $350,000 upfront and up to $91 million in milestones.

“We are pleased with the clinical progress achieved this quarter. Patient enrollment and dosing in the VIRAGE2 trial is progressing well, and we anticipate completing enrollment by the end of the fourth quarter of this year.”

Steven A. Shallcross, Chief Executive Officer of Theriva Biologics

“The recently signed asset sale agreement for SYN-004 (ribaxamase) and the related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. demonstrates our commitment to deriving value from our legacy microbiome programs while continuing to focus on the development of our lead program VCN-01.”

Steven A. Shallcross, Chief Executive Officer of Theriva Biologics
4:06 PM ET 8-K
Divestiture

Theriva Biologics Divestiture to Biossil Labs Inc.

Theriva Biologics completed the sale of its antibiotic-degrading enzyme portfolio, including SYN-004 (ribaxamase), to Biossil Labs Inc. for an upfront payment of $350,000. Theriva is eligible for up to $91 million in regulatory and sales milestones plus royalties, while Biossil assumes all future development costs and responsibilities.

Counterparty
Biossil Labs Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.